METHOD OF DETERMINING A GENOTYPE BY COMPARING THE NUCLEOTIDE SEQUENCE OF MEMBERS OF A GENE FAMILY AND KIT THEREFOR

Abstract: A method is provided for determining a genotype by comparing the nucleotide sequence of members of a gene system which flank the polymorphous sections of the loci of interest. This method is characterized in that the nucleotide sequence of the locus or gene of a strongly conserved section is compared in which the polymorphism is localized.

Description: METHOD OF DETERMINING A GENOTYPE BY COMPARING THE NUCLEOTIDE SEQUENCE O MEMBERS OF A GENE FAMILY AND KIT THEREFOR The invention relates to a method of determining a genotype by comparing members of a gene family, and also to a kit for tracing genetic variations in a gene family, A gene system iβ composed of different loci which are in turn composed of one or more genes; these genes may contain variations, βo- called different alleles, for each system. The immunoglobulin supergene family, which also includes, inter alia, the T-cell receptor, the iaau- noglobulin and the HLA (= human leukocyte antigen) gene systems, is characterised by the presence of a large variation (polymorphism). Each of the genes which form part of the gene systems iβ involved in the immune response in one way or another. Defects in the immune response, which are due to diverse variations in one or more of the gene systems already mentioned, may result in disease. Genetic variation may thus be associated with diseases or disease symptoms. Identification of loci/ alleles may therefore, for example, be of importance in determining the risk of a disease associated with HLA or In detecting variations in the gene system which result in a deviat¬ ion, and variations for which the latter iβ not the case. Thus, the HLΛ- B27 antigen is/are found in $0% of all patients having rheumatoid βpon- dylitis. and HLA-DR3 or HLA-DH- , or both, is/are found in 80X of patients afflicted with insulin-dependent diabetes. Anyone having HLA-B27 has lBO times as much chance of getting rheumatoid spondylitiβ as a person without H A-B27. Table I (taken from Biotβchnologie, een nieuwe indυstriele revolutie (Biotechnology, A New Industrial Revolu¬ tion), Antebl, E. and Fishlock. D., published by Natuur en Techniek, Maastricht/Brussels (1987) page 91) shows the most important diseases which are known to be associated with the HLA system. These locus and allele associations may render clinical practice a great service. They are sometimes used for diagnosis and sometimes in the treatment of certain diseases. They furthermore open up the possibility of proventi- on. It iβ possible to identify those, which have the greatest risk of a particular disease. That iβ very important In those situations in which preventive or early treatment is possible and the development of the disease can be contained. Table I The most important diseases associated with the HLA system HLAs Pathology Relative risk* Al Hodgkin'β disease 1.4 A3 Idiopathlc haemochroaatosis 8.2 B5 Behςet'β disease 6.3 Bl4. B47 Congenital adrenal hyperplaβia 15.4 B27 Rheumatoid βpondylitiβ 67.4 B35 Subacute thyroiditie 13.7 Cw6 Psoriasis 13.3 DR2 Multiple sclerosis 4.1 DR3 Systemic lupus exytheaatosus ζ.S DR3 Addisσn'β disease 6.3 DR3 Baβedow's disease 3.7 DR3 Myaβthenia gravis 2.5 DR3 Ex ramβmbranous glomerulopathy 12.0 DR3 and/or DR4 Insulin-dependent diabetes 6.4 DR3 and/or DR7 Coeliac disease 4.8 DR4 Rheumatoid arthritis 4.0 DR4 Pemphigus 14.4 DR5 Biermer'β anaemia 5.4 DR5 Hashimoto's diβease 5.6 DR5, 0Rw8 Juvenile arthritis 5.2 The relative risk indicates the factor by which the risk of getting a disease iβ multiplied for people having the HLAs concerned. Individuals having group HLA-Cw6 have, for example, 13 * 3 times as much chance of getting psoriasis as people not having said antigen. Genetic variation in the HLA system is furthermore of importance in view of the fact that acceptance in organ and tissue transplantβ lβ associated with the presence of the. same HLA alleles in the white blood cells, while rejection is related to the presence of various HLA alleles in the white blood cells. In man the HLA gene family covers a region of 1,500,000 base pairs. This region codes for many genes. Thus, this region contains, in additi- on to the genes of HLA class I and HI-Λ class II, inter alia, genes of the complement system, 21-hydroχylase genes and genes which code for tumour necrosis factor. The HLA Class I region contains 3 "major" loci: HLA-A, HLA-B and HLA-C. The molecules for which said loci code are expressed in all nucleated cells. The molecules of class I are composed of a polymorphous α-chain having a molecular weight (MW) of 44,000 D and a constant chain, called ^-aicroglobulin, having a MW of 12,000 D. The HLA class II region contains the loci HLA-DR, HLA-DQ and HLΛ-DP. In addition to said loci, a number of genes are also described which do not belong to one of the aboveaentloned loci and are for the time being considered to be separate loci (for example. HLA-E; HLA-F; HLA-DN; HLA-DZ). The molecules of class II are composed of an α-chain (MW 34,000 D) and a β-chain (MW 29,000 D). The α-chain of HLA-DR. iβ constant, i.e. no variants have yet been found. HLA-DR contains 3 P-genes, of which two genes code for a product and one gene is a pβeudogene which is therefore not expressed. Each of the (-.-chains can form dimeric molecules with the σ-chain. The HLA-DQ locus contains four (two α- and two (.-) genes, of which two are expressed, namely DQα and DQP (termed DQA and DQB on the recommendation of the latest nomenclature. committee). The molecule of the other genes (DXA and DXB) has not been found, although the structure of said genes indicates no characteristic pseudogenes. The HLA-DP locus contains four genes (two o and two β),.όf which two are expressed. Polymorphism has not yet been demonstrated for DPA, and only a few alleles of DPB have been described. The other two DP genes are pseudogenes. A method of detecting specific nucleotide variations and genetic polymorphisms which are present in nucleic acids, and also a kit for carrying out said method are described in EP-A-237,362. Said method comprises amplifying nucleic acid sequences in which the presence of nucleotide variations, mutations and polymorphisms is assumed, followed by the detection thereof with al elespecific oligonucleotide sequences using a dot blot. In this process, allele-βpeciflc oligonucleotide sequences are used (see page 22 of the said patent application) which comprise at least the DNA sequence with the variation to be detected and have to be specific for the nucleotide variation to be detected. The kit therefore comprises many different, primers which code for diverse known variations in the DNA sequence, to be investigated, of the gene system. Immobilised sequence-specific oligonucleotide probes for the gene¬ tic analysis of amplified DNA arc disclosed by the International Patent Application W089/11548 and by R. K. Saiki et al.. Proc. Natl. Acad. Sci. USA, 86, 6230-6234 (1989). A method of determining genotypes as regards the alleles in the HLA-DP loci by hybridising nucleic acid samples with a series of probes which are specific for various segments iβ disclosed by the Internatlo- nal Patent Application WO 8911547. A method of distinguishing nucleotide sequences by hybridising amplified DNA with linkable probes iβ disclosed by the International Patent Application WO 90/01563- These known mmthodβ have the following disadvantages: a) It is only possible to trace known variations in the DNA sequen¬ ce of a particular gene system, as a result of which any hitherto un¬ known variations in the gene system to be investigated cannot be die- covered by said method. b) I is necessary to include various oligonucleotideβ for every known variation In the kit and to use them in the method, with the result that, in complex gene systems which comprise many possible alleles (such as, for example, the HLA system), a different oligonucleo¬ tide has to be used for every possible allele and a different hybridisa¬ tion has to be carried out, which iβ cumbersome, time-consuming and , expensive. HLA TYPING Class I aerology The HLA class I molecules are determined with the aid of antisera which are specific for individual alleles. In most cases, alloantisera are used because monoclonal antibodies against all the allele fores are not available. It is improbable that they will become available in the short term because the variation which characterises the polymorphism of the various alleles iβ localised in a small region of the class I gene. Class I protein Protein-chemistry determination of the class I alleles is possible by means of immune precipitations with monoclonal antisera against constant sections of the molecules, followed by iβoeleetric focusing (IEF). Class I DNA Typing is possible to a limited extent by means of determinations of restriction fragment length polymorphism (RFLP) in which use is made of class I cDNA probes. Further refinement has yielded probes which are locus-specific, as a result of which clusters of alleles and some separate alleles can be detected. Typing of class I alleles by means of allele-βpeclfic oligohybridisations (ASO) is not considered possible as a result of the large number of different alleles and, consequently, the large number of oligoβ which is necessary. Routine typing at the DNA level is difficult to'achieve by this method. Claββ II aerology iβ more difficult to carry out in practice, firstly because of the lack of well-defined antisera and secondly because of the elaborateness of the identification technique, viz. two-colour fluores¬ cence. Class II proteins can be characterised by means of EF as a result of the availability of monoclonal antibodies, but the diversity of alleles in terms of variation and number makes the standard typing difficult, especially in heterozygous individuals. Class II DNA RFLP analyses can be used to identify DRA, DQA, DQB and DPB alleles. In this connection, some alleles are placed in a "supβrtypic group" because they cannot be distinguished individually, but stand out as a group of alleles having a specific RFLP pattern from the other alleles. The technique of Southern blot analyses resulting in RFLP patterns iβ readily uβable for typing class II. Viewed technically, this approach is not suitable for routine class II typing because of its elaborate¬ ness. The development of ASO typing with synthetic oligonucleotldes on amplified DNA by means of the polymeraβe chain reaction (PCR) has now made routine typing of DQA possible. Typing will have to be developed still further for DRB, DQB and DPB. A disadvantage of this method is that a large number of allele-specific oligos has to be used as the number of alleles of the locus concerned increases. Workshop Every year the results of the IILA typing centres distributed around the world are examined at a workshop, sera being selected and defined as reference sera. The improvements in typing by means of protein-chemistry determinations. DNA/RFLP and DNΛ-ASO analysis is facilitating the stand¬ ardisation of alleles determined with antisera. As regards protein typing, the workshop determines which monoclonal antibodies have to be used and how the data have to be interpreted. For DNA-RFLP typing, the enzyme-probe combination iβ determined, in addition to a standardisation of DNA isolations and hybridisations. DNA-ASO typing is offered as a package by Perkin-Elπer/Cetus Corpo- ration (patented and marketed as a kit) and can now be used for DQA typing. Attempts are being made to find a combination of the various methods which can be carried out uniformly by every typing centre throughout the world- In this connection, the reproducibility of the determinations in various typing centres, the uniformity of reagβntβ (sera, probes, oligos) and the possibility of carrying out quality controls of the typing play an important role. In the above entioned cases, the approach to typing iβ based on the characterisation of the polymorphous sections of the molecules or genes of the loci. It has now been found that use can advantageously be made of conserved sequences which flank the polymorphous system, to determine genetie variations. The method according to the invention for determining a genotype by comparing the nucleotide sequence of members of a gene system iβ there¬ fore characterised in that the nucleotide βequence of a locuβ or gene of a strongly conserved section is compared in which the polymorphism is localised the genetic material. An important advantage of the method according to the invention is that deviations in a gene system, and especially deviations which are expressed, can be traced more easily and with greater certainty by means of it. More particularly, the advantages of the preβent method are: New mutations can be detected directly and can then be investigated in more detail for functionality. This is in contrast to βerological typing, in which at most a cross reaction with other sera but more often no reaction, is found. ASO typing characterises them as negative for that allele. The method is independent of known polymorphisms compared with other determinations. • Owing to the simplicity of the system (high degree of reproducibi¬ lity throughout the world), standardisation of typing will be simpli¬ fied. The method is independent of geographically determined internal variations in blood cells, serum and expression of the alleles. ~ At the same time the alleles of different loci can be determined in one test, as a result of which the association with diseases becomes known in a broader context (more loci or gene systems). The nomenclature for the gene systems can be localised in a simple manner by definitions of polymorphous parts of the loci/genes by using the invention. The strongly conserved section of the genetic material whose nucle¬ otide sequence iβ compared, according to the invention, has a larger homology than the polymorphous (less conserved) sections whose sequence iβ compared in the known methods. The homology at base level, i.e..the percentage of nucleotideβ which is characteristic of a locus or of the allele forme of the genes iβ at least approximately 502 and preferably at least *. The method according to the invention is especially usable for determining haplotypes of a gene system. In particular, the method can be used to compare loci of a gene system and alleles of a gene system, such as- the gene system of the histocompatlbility system. At the same time, it- may be a matter of a routine determination of alleles in which a specific typing/identifi¬ cation of the presence of an allele is required (for example, in bone marrow transplants or blood transfusions). A gene system which iβ also advantageously suitable for investiga¬ tion with the method according to the invention is a gene system of one of the members of the immunoglobulln supergene family, in particular the genes of an immunoglobulln (Ig) or the genes of the T-cell receptor. (TCR). The method according to the invention is alβo βuitable for research purposes in which a simpler determination of polymorphous sequences other than those which are characteristic for typing iβ possible in a gene as a result of selection of other conserved flanking sequences. The determination of the genotype with the method according to the invention relates, in particular, to tissue typing or cell typing. This can be done, for example, in order to determine the degree of compatibi¬ lity f transplants. If no, or very few, deviations are found in the polymorphous region between donor and acceptor, a transplant will have a high chance of taking because no rejection takes place on the basis of HLAs foreign to the body. It iβ also possible to carry out tiββue typing or cell typing in order to determine the risk of an HLA-asβociatβd disease for an animal. A particular aspect in this connection is the uniform performability and introduction of typing possibilities for, for example, HLA claββ I alleles which could hitherto be determined only by serological techniques. Moreover, a gene system of a bacterium, of a virus or of lipo- proteins can be used aβ the gene system whose genetic variation is investigated. Tho investigation of the possible variation in the nucleotide sequence of a strongly conserved region with the aid of the method according to the invention can readily be carried out if the strongly conserved section to be investigated iβ bounded on at least one side, and preferably on both sides, by a completely conserved sequence, i.e. a sequence which is completely.identical in all .individuals. Said comple¬ tely conserved sequences have, in particular, a length of at least nucleotides and, particularly preferably, a length of at least 10 nucleotideβ. The strongly conserved nucleotide sequences to be investigated can be amplified using the completely conserved sequences. A method which is used with advantage for amplifying the strongly conserved nucleotide sequence lβ a PCR (polymerase chain reaction) (Saiki R.K., βelfand D.H.. Stoffel S., Scharf S.J., Higuchi R. , Horn G.T.. Mulliβ K.B. and Erlich H.A. (1988). Primer directed enzymatic amplification of DNA with a' thermostable DNA poly erase, Science 222.. 487-491). Other methods of amplifying the sequence to be investigated are also usable in the method according to the invention. The sequence amplified in this way can then be βubjected to direct βequence analysis, to denaturing gradient gel electrophoresis (DCGE) or to temperature-gradient gel electrophoreβis (TGGE). The extent to which the denaturing gel system works depends on the discriminating capacity of the gel in relation to the number of different alleles. In other words, the gel system will work well if there lβ only a limited number of alleles of a locus. such as the lipoprotein alleles, HLA-D A alleles, HLA-DPB alleles and possibly HLA-DQB alleles, and virus types, and can be used to determine expression of different loci in different cells or tissues. The amplified DNA or RNA can also be analysed (* typed)by direct sequence determination methods. For routine typing determinations, both analyses may be carried out informatively, reproducibly and in a controlled manner. For gene systems containing several alleles. direct sequence analysis will facilitate the interpretation and therefore the reproducibility by the various centres. The direct βequence analysis method also has advantages for research purposes. Determination of modifications has hitherto been carried out at DNA level by means of Southern blotting. The different families of TCR and Ig genes can be detected by means of specific amplification and sequenc¬ ing or DGGE, while the various members of the family can be distin¬ guished by a set of family-specific primers. Another gene system which is directly suitable for this approach is the determination of diverse viruses, for example HPVI-16. Selection of primers Many alleles of a large number of genes have been sequenced for 5 research purposes. These sequences are stored in the EMBL databank (for Europe) and in the Gene ban (USA), both of which are accessible to subscribers. On the basis of these sequences, the allele-speclfic oligos (ASO), for example, have been selected from the polymorphous regions and these have then been used to identify different alleleβ. Most gene 10 systems contain regions of sequences which are not subject to, hardly subject to or very strongly subject to mutations. For the HLA class II gene system, this has been Investigated in detail in order to localise the polymorphous regions. References: Gustafsβon K.. Emoth E. , Larham er D., Bohme J., Hyldig-Nielβen J.J., Peterβon P.A. and Raβk L. 15 (1984), Mutations and selection in the generation of class II hiβtocoa- pstibility antigen polymorphism. Embo J. £, 1655-1661; Gustafββon K.. Wiaan K., Larhammer D., Raβk L. and Peterson P.A. (1984), Signal sequences distinguish class II histocompatibility antigen beta.chains of different loci, Scand. J. Immunol, lg, 91-97. 20 The presence of usable sequenceβ for the method according to the invention can be detected by more detailed analysis of HLA claββ ' I and II sequences which were available from the sequence databanks (EMBL and Genebank), supplemented by self-determined sequences. Primers for claββ I and other gene, systems have been selected from the sequence databank and can be used. Primers baβed on conserved βequenceβ for the HLA class II loci DRB, DQA, DQB and DPB can be selected on the baβlβ of the sequenceβ already known. Some uβable primers are reported in one of the examples below. It lβ within the scope of the person skilled in the art to select and to test the completely conserved sequences (primers) βuit- 30 able for the typing he plans. Applications To determine lipoprotein polymorphism, the ASO can be radloactlvely labelled and used as a probe for typing the various alleles which are 35. present In lipoprotein E. Three frequently occurring alleles can also be determined by means of restriction enzyme analysis because, in the case of these three alleles in the polymorphous section, the differences are localised at restriction enzyme sites. All five different alleles can be determined directly by a denaturing gel elcctrophorcsls (Sheffield et 0 al.. Identifying DNA polymorphisms by denaturing gradient gel electro- phoreβis, in PCR Protocols: A Guide to Methods and Applications, Academic Press Inc. , 1990. pages 206-218) . There are indications that the different alleles can be detected by direct sequencing since the occurrence of the different alleles is based on differences in nucleo- tide sequences (McBride et al., Cin. Chem. 15, 2196-2201 (1989)). In the case of HLA typing, "constant primers" were used to amplify DRB genes of a family in which an abnormal HLA type occurred. After amplification of the DRB genes, cloning in vectors and subsequent sequence analysis, it was found that, the "abnormal" HLA type is in fact a new haplotype which cannot be detected by known techniques. In this analysis it was found that the identification of the various alleles can be carried out simply by direct sequencing and localisation of the thyaidine nucleotides present in the allele (T-tracking). Automatic βequence determinations have already been carried out for the sequencing of HLA-iX-A (McBride et al., 1989. see above). The method followed by them can be used directly with slight modifications for automatic βequence systems to type the alleles of a locus. After the primers have been selected, "kits" can be assembled for the various gene systems, which kits contain, inter alia, said primers, as a result of which a standardised method iβ obtained for typing the variouβ alleles. In the firβt instance, the ApoE and HLA-DRB, DQA DQB and DPB alleles are investigated for general applicability with denaturing gels and by means of sequence analysis. The invention therefore alβo relates to a kit for tracing genetic variations in a gene family which contains one or two completely conserved sequences having a length of at least 5 nucleotides as primer(β) and possibly other means for amplifying and analysing a strongly conserved section of the genetic material to be investigated, which section iβ flanked by the completely conserved nucleotide βequence(β). EXAMPLE 1 Primers baβed on conserved sequences have been selected for the HLA class II loci DRB, DQA, DQB and DPB and tested for usability. Shown below are the sequences of some universal primers which have been selec¬ ted and tested for an amplification reaction (PCR). Two primers are preferably used for each reaction. DRB5: 5' CC AGC ACG TTT C DRB3: 5* TT GTR TCT OCA 3' (R -- G/A) DQA5: 5' CCA TGA ATT TGA TGG AGA 3' DQA3: 5' ATC GTT TAA TCA 3* DQA3.1: 5* TGT TCA ACT TRT CfϊT TT 3' (R * G/A) DQA3.2: 5* ACA GCS ATG TTT STC AGT GCA 3' (S « 0/C) N.B. DQA5 is uβed in combination with DQA3, DQΛ3-1 or DQA3-2. DXA3.2: 5* ACA GCS ATA TTT STC AGT OCA 3' (S - G/C) DXA3: ' TCT GCS GOT CAA AAC T 3' N.B. DXA3 and DXA3.2 are uβed in combination with DQA.5. DQB5: 5' TGT GCT ACT TCA CCA A 3* QB3: 5' OTA OTT GTG TCT GCA 3' DPB5: 5* GCA GGA ATG CTA CGC GTT TA 3' DPB3: 5' CCA GCT CGT AGT TGT GTC TGC 3' DPB3SP (alternative for DPB3): 5* TTG TAA AAC GAC GGC CAG TCC AGC TCG TAG TTG TOT CTG C 3' APOE.F4:5' ACA GAA TTC CCC CCG GCC TGG TAC AC V APOE.F6:5' TAA GCT TGG CAC GGC TGT CCA AGO A 3' The coabinationβ DRB5/DRB3. DQA5/DQA3.2 and DPB5/DPB3SP have been βuc- cessfully uβed for βequenceβ. EXAMPLE 2 In the family G (two parents, four children) cross reaction was found in the determination for HLA class II alleles having different typing sera by means of the conventional HLA typing, method. It was not possible to establish any typing by this means. More detailed analysis by means of restriction fragment length polymorphism (RFLP) and ASO typing resulted in the hypothesis that it was not two alleles of HLA-DRB which occurred in this family in different members of the family, but three, and thiβ had implications for a disease of one of the members of the family to be treated (Tilanus M.G.J., Van Eggermond M.C.J.A., Fei H. , Scheuder G.M.Th. and Giphart M.J. (1989), Family with an apparent HLA-DR triplet: Evidence for exchange of functional HLA-DR beta genes between different haplotypes, Exp. Clln. Immunogenetics 6, 162-168). The DNA of this family was studied in more detail in order to be able to establish the genetic basis for this phenomenon. One of the techniques which was uβed in doing this consisted of βequence analysis of the various alleles of HLA class II loci. In this family, three DRB alleles have been identified in the DNA of one person, viz. DR1. DR2 and DR 6, on the basis of positive identi¬ fication with allele-specific oligos (triplet). The allele-specific oligoβ detect the corresponding sequences for the regions which also differ at protein level. Figure 1 shows the nucleotide βequence of DR1 with the derived amino acid βequence in three-letter and one-letter code. The underlined regions indicate the location of allele-βpecific oligoβ. The nucleotide βequence and the associated amino acid βequence of the allele-specific oligonucleotideβ of the other alleles present in this family are shown in Figures 2a and 2b. Figure 2a βhows the nucleo¬ tide variation in a first polymorphous region and Figure 2b that in a second polymorphous region, corresponding to the underlined regions in Figure 1. For a more detailed analysis of the DRB genes, the universal primers DRB5S and DRB3E described were used. In a control study, the use of the universal primers for identification of the DRB alleles DR1. DR2 and DRw6 was teeted, but no deviations were found in these βequen- ces. The reβultβ of the βequence analysis of control cell lines and DNA of family G are shown in Figures 3a and 3b, respectively, in the form of the amino acid sequence using the one-letter code. It lβ evident from this that there iβ a recombined haplotype in this family, DR1 and DR2 alleles being involved. The DRw6.wl9 and DRw6,52 c alleles are identical to the control sequences. It appears that the alleles which are detected by the DRl-βpeclfic oligos and by the DR2-specific oligo occur next to each other (Figure 4). There is there¬ fore no question of three alleles being present here but of a DRB haplo¬ type not previously identified. In another section of the gene, a βpeci- fie sequence has been identified for this DR1 ♦ 2 haplotype. Of other loci (DQB,, DQA and DPB) in this family, it haβ now been established by using universal primers that there are also only two (unmutated) alleles. In addition, said haplotype can be characterised by the presence of conserved specific sequences.

Claims: CLAIMS 1. Method of determining a genotype by comparing the nucleotide βequence of members of a gene system, characterised in that the nucleo¬ tide sequence of a strongly conserved section of the genetic material is compared. 2. Method according to Claim 1, characterised in that the strongly conserved section of the genetic material has a homology of at least 58*. 3. Method according to Claim 1 or 2. characterised in that haplotypes of a gene system are determined. 4. Method according to Claim 3, characterised in that loci of a gene system are compared. 5- Method according to Claim 4. characterised in that alleles of a gene system are compared. 6. Method according to any of Claims 3~5. characterised in that a gene system of the histocompatibilty system lβ uβed as gene ayetea. 7. Method according to Claim 1 or 2, characterised i that a gene βyβtea of one of the members of the immunoglobulln βupergene family iβ uβed as gene system. 8. Method according to Claim 7, characterised in that the gene system of an immunoglobulln iβ used as gene system. 9- Method according to Claim 7, characterised in that the gene eyetern of the T-cell receptor is uβed as gene system. 10. Method according to Claim 1 or 2, characterised in that tiββue typing or cell typing iβ carried out. 11. Method according to Claim 10, characterised in that the degree of compatibility of transplants or cells is determined. 12. Method according to Claim 10, characterised in that the rlβk is determined for a person or animal of a disease asβociated with HLA (human leucocyte antigen) or MHC (major histocompatibility complex). 13 * Method according to Claim 1 or 2, characterised in that a gene system of a bacterium or of a virus iβ uβed aβ gene system. 14. Method according to any of the preceding claims, characterised in that the strongly conserved section is flanked by completely conserved sequences of at leaβt 5 nucleotides. 15. Method according to Claim 14. characterised in that the completely conserved βequenceβ contain at least 10 nucleotides. 16. Method according to Claim 34 or 15, characterised in that the strongly conserved nucleotide βequence is amplified making use of the completely conserved sequences. 17- Method according to Claim 16. characterised in that the strongly conserved nucleotide sequence is amplified using a PCR (polymerase chain reaction). 18. Method according to Claim 16 or 17, characterised in that the amplified βequence is βubjected to direct sequence-analysis. 19- Method according to Claim 16 or 17, characterised in that the amplified sequence iβ subjected to denaturing gradient gel electro- phoreais (DGGE) . 20. Method according to Claim 16 or 17, characterised in that the amplified sequence iβ βubjected to temperature-gradient gel electro- phoreβiβ (TGGE). 21. Kit for tracing genetic variations in a gene family which contains one or two completely conserved nucleotide sequences having a length of at least 5 nucleotides as prime (β) and possibly other means for ampli- fying and analysing a strongly conserved βectlon of the genetic material to be inveβtigated, which βection is flanked by the completely conserved nucleotide βequence(s).

Inventors: TILANUS MARCEL G J, TILANUS, MARCEL, G., J.
Applicants: APPLIED BIOSYSTEMS, APPLIED BIOSYSTEMS, INC.
Application year: 1991
Main classification: C07H15
IPC codes: C12N15, C12Q1, G01N33